Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

ABSTRACT:

Background

Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis.

Methods

An open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined

SUBMITTER: Sweiss NJ 

PROVIDER: S-EPMC4134103 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature